Glioblastoma and other primary brain malignancies in adults: a review

LR Schaff, IK Mellinghoff - Jama, 2023 - jamanetwork.com
Importance Malignant primary brain tumors cause more than 15 000 deaths per year in the
United States. The annual incidence of primary malignant brain tumors is approximately 7 …

Isocitrate dehydrogenase (IDH) mutant gliomas: a Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions

JJ Miller, LN Gonzalez Castro, S McBrayer… - Neuro …, 2023 - academic.oup.com
Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group

P Karschnia, JS Young, A Dono, L Häni… - Neuro …, 2023 - academic.oup.com
Background Terminology to describe extent of resection in glioblastoma is inconsistent
across clinical trials. A surgical classification system was previously proposed based upon …

Emerging role of artificial intelligence in diagnosis, classification and clinical management of glioma

J Luo, M Pan, K Mo, Y Mao, D Zou - Seminars in Cancer Biology, 2023 - Elsevier
Glioma represents a dominant primary intracranial malignancy in the central nervous
system. Artificial intelligence that mainly includes machine learning, and deep learning …

[HTML][HTML] Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective …

K Zhang, X Liu, G Li, X Chang, S Li, J Chen… - Cancer biology & …, 2022 - ncbi.nlm.nih.gov
Objective: We aimed to summarize the clinicopathological characteristics and prognostic
features of various molecular subtypes of diffuse gliomas (DGs) in the Chinese population …

[HTML][HTML] Diagnostic yield and complication rate of stereotactic biopsies in precision medicine of gliomas

S Katzendobler, A Do, J Weller, MM Dorostkar… - Frontiers in …, 2022 - frontiersin.org
Background An integrated diagnosis consisting of histology and molecular markers is the
basis of the current WHO classification system of gliomas. In patients with suspected newly …

[HTML][HTML] Therapies for IDH-mutant gliomas

R Alshiekh Nasany, MI de la Fuente - Current neurology and neuroscience …, 2023 - Springer
Abstract Purpose of Review Isocitrate dehydrogenase (IDH) mutant gliomas are a distinct
type of primary brain tumors with unique characteristics, behavior, and disease outcomes …

Tumor volume growth rates and doubling times during active surveillance of IDH-mutant low-grade glioma

A Bhatia, R Moreno, AS Reiner, S Nandakumar… - Clinical Cancer …, 2024 - AACR
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain
tumors characterized by a slow-growing phase over several years followed by a rapid …

[HTML][HTML] Surgical management of Glioma Grade 4: Technical update from the neuro-oncology section of the Italian Society of Neurosurgery (SINch®): A systematic …

T Ius, G Sabatino, PP Panciani, MM Fontanella… - Journal of neuro …, 2023 - Springer
Purpose The extent of resection (EOR) is an independent prognostic factor for overall
survival (OS) in adult patients with Glioma Grade 4 (GG4). The aim of the neuro-oncology …

[HTML][HTML] Nanoparticles for diagnosis and target therapy in pediatric brain cancers

C Guido, C Baldari, G Maiorano, A Mastronuzzi… - Diagnostics, 2022 - mdpi.com
Pediatric brain tumors represent the most common types of childhood cancer and novel
diagnostic and therapeutic solutions are urgently needed. The gold standard treatment …